drugset / Trial / NCT04281498
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Phase 2
Completed
6 enrolled
John Mascarenhas
Celgene Corporation · collabIncyte Corporation · collabMyeloproliferative Neoplasms Research Consortium · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
The presence of IDH mutation is associated with worse survival in patients with myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and enasidenib an IDH2 inhibitor are effective and tolerable treatments for patients with myelofibrosis (MF) and acute myeloid leukemia (AML), respectively. The study team hypothesize that the combination of these agents in patients with MPN with an IDH2 mutation will improve the overall clinical response to therapy.
Timeline
- Start
- 2021-01-14
- Primary completion
- 2023-05-30
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enasidenib | Small molecule | 50 mg | Oral |
| Subject | Enasidenib | Small molecule | 100 mg | Oral |
| Subject | Ruxolitinib | Small molecule | — | Oral |